Literature DB >> 3021693

Influence of WR 2721 on radiation response of canine soft tissue sarcomas.

S L McChesney, E L Gillette, M W Dewhirst, S J Withrow.   

Abstract

Seventy-three dogs with soft tissue sarcomas were randomized to 2 dose response assays to receive irradiation alone or with the radioprotector WR-2721. Nausea and vomiting were the major side effects of WR-2721 administration although one death occurred because of cardiac and respiratory failure which may have been caused by the WR-2721. There was no change in blood counts or serum chemistry values. The TCD50/lyr was 52 Gy delivered in 10 fractions for both groups. However, there was an indication of tumor protection at lower doses because at all comparable dose levels the percentage tumor control was lower in dogs given WR-2721. There was no decrease in acute skin reactions of dogs treated with WR-2721 and little, if any, protection against fibrosis, soft tissue necrosis or bone necrosis. The lack of protection of normal tissues may have been caused by fractionation. The agent may be more useful combined with large single doses such as given in intraoperative radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021693     DOI: 10.1016/0360-3016(86)90132-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy.

Authors:  Donald E Thrall; Susan M LaRue; Daohai Yu; Thaddeus Samulski; Linda Sanders; Beth Case; Gary Rosner; Chieko Azuma; Jeannie Poulson; Amy F Pruitt; Wilma Stanley; Marlene L Hauck; Laurel Williams; Paul Hess; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 3.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

4.  Photodynamic hyperthermal chemotherapy with indocyanine green in feline vaccine-associated sarcoma.

Authors:  Masaki Onoyama; Takeshi Tsuka; Tomohiro Imagawa; Tomohiro Osaki; Akihiko Sugiyama; Kazuo Azuma; Norihiko Ito; Kazuhiko Kawashima; Yoshiharu Okamoto
Journal:  Oncol Lett       Date:  2015-08-03       Impact factor: 2.967

5.  Outcomes of Spatially Fractionated Radiotherapy (GRID) for Bulky Soft Tissue Sarcomas in a Large Animal Model.

Authors:  Michael W Nolan; Tracy L Gieger; Alexander A Karakashian; Mariana N Nikolova-Karakashian; Lysa P Posner; Donald M Roback; Judith N Rivera; Sha Chang
Journal:  Technol Cancer Res Treat       Date:  2017-02-07

6.  Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma.

Authors:  Masaki Onoyama; Takeshi Tsuka; Tomohiro Imagawa; Tomohiro Osaki; Saburo Minami; Kazuo Azuma; Kazuhiko Kawashima; Hiroshi Ishi; Takahiro Takayama; Nobuhiko Ogawa; Yoshiharu Okamoto
Journal:  J Vet Sci       Date:  2013-10-18       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.